Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
- PMID: 2167514
- DOI: 10.1126/science.2167514
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
Abstract
Primary and secondary hypertriglyceridemia is common in the general population, but the biochemical basis for this disease is largely unknown. With the use of transgenic technology, two lines of mice were created that express the human apolipoprotein CIII gene. One of these mouse lines with 100 copies of the gene was found to express large amounts of the protein and to be severely hypertriglyceridemic. The other mouse line with one to two copies of the gene expressed low amounts of the protein, but nevertheless manifested mild hypertriglyceridemia. Thus, overexpression of apolipoprotein CIII can be a primary cause of hypertriglyceridemia in vivo and may provide one possible etiology for this common disorder in humans.
Similar articles
-
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.J Clin Invest. 1992 Nov;90(5):1889-900. doi: 10.1172/JCI116066. J Clin Invest. 1992. PMID: 1430212 Free PMC article.
-
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.J Clin Invest. 1997 Jun 1;99(11):2672-81. doi: 10.1172/JCI119456. J Clin Invest. 1997. PMID: 9169497 Free PMC article.
-
Lipoprotein analysis in transgenic mice expressing human apolipoprotein (apo) A-I and apo C III: use of micromethods in analysis of lipoprotein system in mice.Hokkaido Igaku Zasshi. 1994 Mar;69(2):312-26. Hokkaido Igaku Zasshi. 1994. PMID: 8157256
-
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.Atheroscler Suppl. 2017 Nov;30:19-27. doi: 10.1016/j.atherosclerosissup.2017.05.003. Epub 2017 May 31. Atheroscler Suppl. 2017. PMID: 29096837 Review.
-
Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.Ann Biol Clin (Paris). 1989;47(8):497-501. Ann Biol Clin (Paris). 1989. PMID: 2690681 Review.
Cited by
-
Development of Antisense Drugs for Dyslipidemia.J Atheroscler Thromb. 2016 Sep 1;23(9):1011-25. doi: 10.5551/jat.RV16001. Epub 2016 Jul 27. J Atheroscler Thromb. 2016. PMID: 27466159 Free PMC article. Review.
-
Hyperlipidaemia and cardioprotection: Animal models for translational studies.Br J Pharmacol. 2020 Dec;177(23):5287-5311. doi: 10.1111/bph.14931. Epub 2020 Jan 17. Br J Pharmacol. 2020. PMID: 31769007 Free PMC article. Review.
-
Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins.Am J Hum Genet. 1998 Feb;62(2):406-19. doi: 10.1086/301712. Am J Hum Genet. 1998. PMID: 9463319 Free PMC article.
-
Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis.Afr Health Sci. 2020 Dec;20(4):1800-1808. doi: 10.4314/ahs.v20i4.34. Afr Health Sci. 2020. PMID: 34394242 Free PMC article.
-
Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.J Lipid Res. 2016 May;57(5):894-905. doi: 10.1194/jlr.P064816. Epub 2016 Mar 3. J Lipid Res. 2016. PMID: 26945091 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases